Between late 2023 and early 2026, the FDA moved 19 widely used peptides to its Category 2 restricted list (banning them from licensed compounding), shut down compounded semaglutide and tirzepatide production after resolving the GLP-1 drug shortages, and then — on February 27, 2026 — HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides would be moved back to Category 1, potentially restoring legal compounding access through licensed pharmacies with a physician's prescription.
This 2-year period represents the most significant regulatory disruption to the peptide therapy market in history, and it involves three separate but overlapping events: the Category 2 peptide compounding ban, the GLP-1 compounding shutdown, and the announced reclassification reversal. Each operates under different legal mechanisms, affects different compounds, and has different implications for patients, clinicians, compounding pharmacies, and research peptide buyers. The practical result: a gray market in unregulated peptides exploded, millions of patients lost access to physician-supervised therapy, and the regulatory landscape now sits in flux between announcement and implementation. For the country-by-country legal framework that applies outside the United States, Peptigrity's guide to peptide legality and regulatory status by country covers the international context.
What Are the FDA's Compounding Categories? Category 1, 2 & 3 Explained
The FDA classifies bulk drug substances into 3 categories for compounding purposes — Category 1 (eligible to compound), Category 2 (safety concerns identified, compounding banned), and Category 3 (under review) — and the movement of peptides between these categories is what created the regulatory upheaval of 2025-2026.
Category 1 substances are eligible for compounding under both Section 503A (traditional compounding pharmacies filling patient-specific prescriptions under state oversight) and Section 503B (FDA-registered outsourcing facilities operating under cGMP standards that can produce larger batches). These substances have been evaluated and deemed to have adequate safety and usage data for compounding. Examples of peptides that remained in Category 1 throughout the 2023-2026 period include sermorelin and NAD+.
Category 2 substances have been identified by the FDA as presenting "potential significant safety risks" and are not eligible for routine compounding. Placement in Category 2 effectively bans licensed compounding pharmacies from preparing these compounds. The FDA's stated rationale for Category 2 placement typically centres on insufficient human safety data, concerns about immunogenicity (the risk of triggering immune reactions), and the potential for aggregation in compounded formulations. This is where the 19 peptides were moved in late 2023.
Category 3 substances have insufficient information for full evaluation and remain under review — not yet classified into either Category 1 or Category 2.
The distinction between 503A and 503B matters for understanding enforcement timelines. Section 503A pharmacies compound patient-specific prescriptions under state pharmacy board oversight. Section 503B outsourcing facilities are registered with the FDA, subject to FDA inspection, must follow current Good Manufacturing Practices (cGMP), and can produce larger batches without individual patient prescriptions. Both pathways depend on the bulk drug substance being classified as Category 1.
The most misunderstood point in the current discourse: Category 1 does not mean FDA-approved. Compounding eligibility means pharmacies can legally prepare the compound with a physician's prescription, but the compound remains an unapproved drug — it has not undergone the Phase I through Phase III clinical trials and New Drug Application (NDA) or Biologics License Application (BLA) review process that FDA approval requires. As Holt Law's regulatory analysis emphasises, this distinction is critical for both providers and patients.
The Complete Timeline — What Happened and When
The regulatory events of 2025-2026 unfolded in three overlapping waves — the Category 2 peptide compounding ban, the GLP-1 shortage resolution and compounding shutdown, and the announced reclassification reversal — and the following timeline tracks each event by date.
Late 2023: The Category 2 Ban
The FDA moved 19 peptides from Category 1 to Category 2 on the Section 503A bulk drug substances list. Affected compounds included BPC-157, TB-500 (Thymosin Beta-4), Thymosin Alpha-1, CJC-1295, ipamorelin, AOD-9604, Selank, Semax, GHK-Cu, MOTS-C, KPV, and others. Licensed compounding pharmacies could no longer legally prepare these compounds. The FDA cited insufficient human safety data, concerns about immunogenicity, and aggregation risk as justification. Critics — including healthcare providers, compounding pharmacy groups, and patient advocates — argued the agency overstepped its authority and that no specific safety signal justified the restriction for most of the affected peptides.
October 2024: Tirzepatide Shortage Resolved
The FDA removed tirzepatide (Mounjaro/Zepbound) from the drug shortage list after manufacturer Eli Lilly confirmed that production capacity could meet national demand. Compounders were required to begin winding down tirzepatide production.
December 2024: Tirzepatide Enforcement Timeline Set
The FDA issued a declaratory order reaffirming the tirzepatide shortage resolution. 503A pharmacies were given until February 18, 2025; 503B outsourcing facilities until March 19, 2025 to cease compounding tirzepatide.
January 2025: Interim Policy Enforced
The FDA enforced revisions to its interim policy on bulk drug substances, further limiting compounding pharmacy use of Category 2 substances. Industry coverage described this as "the peptide crackdown."
February 2025: Semaglutide Shortage Resolved
On February 21, the FDA marked the semaglutide (Ozempic/Wegovy) shortage as resolved. 503A compounding pharmacies were given until April 22, 2025; 503B facilities until May 22, 2025. On February 24, the Outsourcing Facilities Association (OFA) filed a lawsuit challenging the semaglutide shortage determination.
March 2025: Research Peptide Guidance and Tirzepatide Deadline
The FDA issued its Final Guidance on research-grade peptides — establishing new labelling requirements, institutional verification protocols, and explicit prohibitions on consumer-facing marketing for research-use-only compounds. Enforcement became effective January 2026. The tirzepatide 503B compounding deadline (March 19) passed. As Frier Levitt's legal analysis noted, compounding facilities were required to align operations with the post-shortage regulatory framework.
April–May 2025: GLP-1 Compounding Effectively Ends
The semaglutide 503A deadline passed (April 22). The court denied OFA's preliminary injunction for semaglutide (April 24). The semaglutide 503B deadline passed (May 22). The court upheld the FDA's tirzepatide shortage determination (May 7). Compounded GLP-1 production effectively ended for most facilities, though some companies continued offering "personalised" formulations under contested legal theories.
December 2025: Legislative Action and Gray Market Exposure
The SAFE Drugs Act (H.R. 6509) was introduced in Congress, proposing further compounding restrictions. Separately, a December 2025 investigation found widespread availability of unregulated peptides on major retail platforms, with no guarantees of purity or safety — illustrating the gray market that had grown in response to the compounding restrictions.
February 27, 2026: The Reclassification Announcement
HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience (Episode #2461) that approximately 14 of the 19 Category 2 peptides would be moved back to Category 1, restoring eligibility for legal compounding. His core argument: the FDA was legally required to identify a specific safety signal — evidence of actual harm — to justify restricting each peptide, and for most compounds, no such signal existed. As PeptideJournal's coverage noted, Kennedy also acknowledged that the restrictions had "created the gray market" by pushing patients toward unregulated vendors.
As of April 2026: No Formal Action Published
No Federal Register notice has been issued. No updated Category list has been released. The February announcement signals intent but is not completed regulatory action. Compounding pharmacies that resume production of Category 2 peptides before formal reclassification face regulatory and legal risk. The announcement is significant — but it is not yet implementation.
Which Peptides Were Affected? The Full Category 2 List
The FDA moved 19 peptides to its Category 2 restricted list between late 2023 and December 2024, and HHS Secretary Kennedy's February 2026 announcement indicated that approximately 14 of these would return to Category 1 — but as of April 2026, the specific list of which 14 return and which 5 remain restricted has not been formally published.
The 19 Peptides Moved to Category 2
The compounds affected by the Category 2 classification include BPC-157, TB-500 (Thymosin Beta-4), Thymosin Alpha-1, CJC-1295, ipamorelin, AOD-9604, Selank, Semax, GHK-Cu, MOTS-C, KPV, Dihexa, DSIP, Epithalon, Hexarelin, Kisspeptin, Melanotan II, and others. The FDA's official Category 2 list provides the definitive reference.
The ~14 Expected to Return to Category 1
Based on the February 2026 announcement and subsequent reporting, the peptides expected to be reclassified include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, ipamorelin, AOD-9604, Selank, Semax, KPV, MOTS-C, GHK-Cu, and potentially others. However, the specific list has not been confirmed by formal FDA action. Any claims about which exact compounds return are based on reporting and analysis of the announcement, not on a published regulatory document.
The ~5 Expected to Remain Restricted
The announcement stated "approximately 14 of 19," implying approximately 5 peptides would remain on the Category 2 list. These are likely compounds where the Pharmacy Compounding Advisory Committee (PCAC) review identified specific safety concerns or where the safety profile was considered weakest. Five peptides — CJC-1295, ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank — have been under active PCAC review with dedicated meeting evaluations. Whether these are the 5 that remain restricted, or whether the PCAC review actually supports their reclassification, is unknown until the formal list is published.
Peptides Never Affected
Sermorelin — the unmodified GHRH analog (GRF 1-29) that was FDA-approved from 1997 to 2008 — was never moved to Category 2 and remained legal to compound throughout the entire 2023-2026 period. NAD+ and various amino acid-based compounds were similarly unaffected. The GLP-1 drugs (semaglutide, tirzepatide, liraglutide) were also not Category 2 — their compounding was governed by a completely separate mechanism tied to shortage list status.
The GLP-1 Compounding Shutdown — Semaglutide and Tirzepatide
The compounded semaglutide and tirzepatide shutdown is legally separate from the Category 2 peptide ban — these are FDA-approved drugs whose compounding was permitted only during drug shortages, and both shortages were declared resolved in late 2024 to early 2025, triggering wind-down deadlines that have now passed.
The legal mechanism is different from the Category system. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are fully FDA-approved medications with completed Phase III clinical trials. Under normal circumstances, compounding pharmacies cannot produce "essentially copies" of commercially available FDA-approved drugs. The exception: when those drugs appear on the FDA's drug shortage list, 503B outsourcing facilities gain authority to compound them to meet patient need. Both semaglutide and tirzepatide were on the shortage list from 2022 due to overwhelming demand, enabling a massive compounding industry that served an estimated 3.7 million patients with compounded GLP-1 medications at a fraction of brand-name cost — typically $150-400/month compared to Wegovy's ~$1,349/month list price.
When the shortages were resolved (tirzepatide in October 2024, semaglutide in February 2025), the legal basis for compounding was removed. The OFA filed lawsuits challenging both determinations, but courts upheld the FDA's authority. By May 2025, enforcement discretion periods for both compounds had expired.
The current status (April 2026): compounded GLP-1 medications are largely unavailable through standard 503B channels. 503A pharmacies may still prepare compounded semaglutide or tirzepatide for patients with documented medical necessity — such as an allergy to an inactive ingredient in the branded product or a need for a non-standard dose — but not as routine cost-saving substitution. Some telehealth companies continue offering "personalised" GLP-1 formulations with modified doses or added ingredients, arguing these are not "essentially copies." The legality of this approach is actively contested, and as GoodRx's analysis notes, compounded GLP-1s were never intended as a long-term substitute for FDA-approved options. The FDA has received over 455 adverse event reports for compounded semaglutide and over 320 for compounded tirzepatide as of early 2025, primarily related to dosing errors from patient self-measurement.
The February 2026 Reclassification Announcement — What It Means and What It Doesn't
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 Category 2 restricted peptides would be returned to Category 1 — but as of April 2026, no formal regulatory action has been published, meaning the announcement signals intent, not implementation, and compounding pharmacies cannot legally resume production of Category 2 peptides until a formal Federal Register notice or updated FDA list is issued.
What Was Said
During a conversation on the Joe Rogan Experience (Episode #2461), Kennedy stated that the FDA was legally required to identify a specific safety signal — evidence of actual harm — to justify placing each peptide on the restricted list. For most of the 19 compounds, he argued, no such signal existed. The original restrictions were based on a lack of efficacy data and insufficient human safety studies — not on evidence of harm. These are different legal standards, and Kennedy argued the FDA was applying the wrong one. He also made a significant acknowledgment about the consequences of the ban: by cutting off legal access through licensed compounding pharmacies, the restrictions pushed patients toward unregulated online vendors, effectively "creating the gray market."
What It Means (If Implemented)
If the reclassification is formalised, licensed 503A and 503B compounding pharmacies would once again be able to legally prepare these peptides with a valid physician's prescription. Patients who previously received BPC-157, Thymosin Alpha-1, CJC-1295/ipamorelin, and other compounds through physician-supervised compounding would regain legal access through regulated channels with USP 797/795 quality standards.
What It Does Not Mean
It is not FDA approval. These peptides remain unapproved drugs without Phase III clinical trial data. Category 1 status means pharmacies can compound them — it does not certify them as safe and effective through the standard FDA approval process.
It is not completed regulatory action. No Federal Register notice has been published. No updated Category list has been released on the FDA website. As of April 2026, this remains announced intent.
It is not a green light to compound immediately. Pharmacies that resume compounding Category 2 peptides before formal reclassification face regulatory risk, potential warning letters, and legal liability.
It is not relevant to the GLP-1 compounding shutdown. The GLP-1 issue is governed by shortage list status, not Category classification. Semaglutide and tirzepatide compounding restrictions are legally separate and not affected by the Category reclassification.
What to Watch
The specific milestones to monitor: a formal Federal Register notice confirming the reclassification, publication of the updated Category list on the FDA website, PCAC meeting outcomes for the 5 peptides under active committee review, legislative progress on the SAFE Drugs Act (H.R. 6509) which proposed further compounding restrictions, and compounding pharmacy supply chain readiness (raw material sourcing was disrupted by the original ban and will take time to restore).
During this period of regulatory uncertainty, the quality of peptides available through any channel — compounding, research, or gray market — depends on independent verification. Peptigrity's reviewed peptide shops provide vendor-independent quality data, and the platform's independent lab tests verify compound identity and purity regardless of the source.
What Does This Mean for Research-Use-Only (RUO) Peptide Buyers?
The Category 2 reclassification, if implemented, restores compounding pharmacy access — but it does not directly change the legal status of research-use-only (RUO) peptide vendors, who operate under a separate regulatory framework that the FDA tightened independently in March 2025 with new labelling, verification, and enforcement rules effective January 2026.
RUO peptides occupy a legally distinct category from compounded pharmaceuticals. They are sold as chemical reagents for laboratory research — not as medications, not by pharmacies, and not with physician prescriptions. The FDA's position is clear: peptides marketed to consumers, shipped to residential addresses, or labelled with therapeutic claims or dosing instructions are considered intended for human use regardless of "research use only" disclaimers, and they violate federal misbranding statutes.
The March 2025 Final Guidance tightened this enforcement framework specifically. New requirements include explicit "not for human use" labelling on every vial, institutional verification protocols (the vendor must confirm the buyer has a research affiliation), verifiable chain-of-custody records demonstrating research intent, and an explicit prohibition on consumer-facing marketing. Enforcement became effective in January 2026, and the FDA presumes any peptide shipped to a residential address or ordered by an individual without institutional affiliation is intended for human use.
The Category 2 reclassification does not change this framework. Even when BPC-157 returns to Category 1, that means compounding pharmacies can prepare it — the legal status of RUO vendors selling the same compound as a research chemical is a separate regulatory question governed by different statutes.
The gray market reality is that during the Category 2 ban, enormous demand shifted from compounding pharmacies to RUO vendors. Many of these operate without pharmaceutical oversight, and quality varies from excellent to non-existent. The HPLC purity confirmation and mass spectrometry identity verification that a licensed compounding pharmacy provides by default are not guaranteed from unregulated sources. This is precisely where Peptigrity's independent verification fills the gap: the platform's peptide purity standards guide explains what analytical quality means, the how to verify peptide quality before you buy framework provides actionable verification steps, and the independent lab tests and testing methods guide help buyers confirm what is actually in the vial.
Both the WADA Prohibited List (which classifies most healing and growth hormone peptides under S2 — prohibited in and out of competition) and the FDA's enforcement framework remain in force regardless of the Category reclassification. Legal access through compounding does not change sport prohibition or the research-use restrictions on RUO products.
Frequently Asked Questions
Does reclassification to Category 1 mean these peptides are now FDA-approved?
No. Category 1 means compounding pharmacies can legally prepare them with a physician's prescription — it does not mean the FDA has reviewed and approved them as safe and effective drugs through the standard NDA/BLA approval process. These remain unapproved drugs prepared under USP compounding standards (797/795), not under FDA manufacturing oversight. The distinction matters: FDA-approved drugs like semaglutide (Ozempic) have undergone Phase I through Phase III clinical trials involving thousands of participants. Compounded Category 1 peptides have not.
Can I get BPC-157 from a compounding pharmacy right now (April 2026)?
Not yet. As of April 2026, BPC-157 remains on the Category 2 restricted list. The February 2026 announcement signals that it is expected to return to Category 1, but no formal regulatory action has been published — no Federal Register notice, no updated Category list. Compounding pharmacies that prepare BPC-157 before official reclassification are operating outside current federal rules and face regulatory risk. Monitor the FDA's bulk drug substances page for the formal updated list.
Is compounded semaglutide still available?
In limited circumstances. The semaglutide shortage was resolved in February 2025, and enforcement discretion deadlines for 503A pharmacies (April 22, 2025) and 503B facilities (May 22, 2025) have both passed. Compounding pharmacies can no longer routinely produce "essentially copies" of FDA-approved semaglutide. However, 503A pharmacies may still prepare compounded semaglutide for patients with documented medical necessity — for example, an allergy to an inactive ingredient in the branded product, or a clinical need for a non-standard dose not commercially available. Some companies are offering "personalised" formulations with dose modifications, but the legality of this workaround is contested by both the FDA and brand-name manufacturers.
Which 5 peptides are expected to remain restricted?
The specific 5 peptides that may remain on the Category 2 list have not been formally identified. The February 2026 announcement stated "approximately 14 of 19" would be reclassified, implying approximately 5 would remain restricted — likely those where PCAC review identified specific safety concerns or where the safety profile was considered weakest. Five peptides have been under active PCAC review (CJC-1295, ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank), but whether these are the 5 that stay restricted or the 5 whose review supports reclassification is unknown. Until the formal FDA list is published, any claims about which specific peptides remain restricted are speculative.
How does this affect peptide buyers outside the United States?
The FDA Category system applies only to US-based compounding pharmacies. International buyers are governed by their own country's regulatory framework — the TGA in Australia, MHRA in the UK, EMA in Europe, Health Canada in Canada. The RFK reclassification announcement has no direct legal effect outside the United States. However, the Category 2 restrictions did affect the global supply chain because many API (active pharmaceutical ingredient) manufacturers adjusted production volumes based on US regulatory signals and demand patterns. Reclassification may indirectly improve global supply by restoring demand signals to API manufacturers. For the full international regulatory framework, Peptigrity's guide to peptide legality by country covers the relevant jurisdictions.
This article reflects the regulatory landscape as understood in April 2026. Regulations are evolving — monitor the FDA's official publications for formal updates. This article is for educational and informational purposes only and does not constitute legal or medical advice. Always consult a qualified healthcare provider and legal counsel regarding peptide therapy and compounding compliance. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products, vendors, or compounding
